| Accession |
PRJCA008867 |
| Title |
Neoadjuvant chemo-free combination of camrelizumab and apatinib for locally advanced resectable oral squamous cell carcinoma |
| Relevance |
Medical |
| Data types |
Genome sequencing
|
| Organisms |
Homo sapiens
|
| Description |
Novel neoadjuvant therapy regimens are needed to improve the outcomes of patients with locally advanced resectable oral squamous cell carcinoma. Our findings demonstrate that neoadjuvant therapy with a chemo-free combination of camrelizumab and apatinib is safe and yields a promising MPR rate, supporting further trials. |
| Sample scope |
Multiisolate |
| Release date |
2022-03-28 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 36104359
|
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
|
Nature Communications
|
10.1038/s41467-022-33080-8
|
2022
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| National Natural Science Foundation of China (NSFC)
|
General Program
|
81972525
|
Molecular mechanism of erbB2 pathway and recombinant GDF15 on personalized treatment on the basis of GDF15 expression in oral squamous cell carcinoma
|
|
|
| Submitter |
Lai-ping
Zhong (zhonglp@hotmail.com)
|
| Organization |
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine |
| Submission date |
2022-03-28 |
